W Health Ventures Marks Close Of Fund II At ₹700 Cr
Healthtech-focused VC firm W Health Ventures has closed its second fund at ₹700 Cr (about $84 Mn), sailing past its…
W Health Ventures, a venture capital firm specializing in healthtech, has successfully closed its second fund at ₹700 Cr ($84 Mn), surpassing its initial target of ₹630 Cr. The limited partners (LPs) included family offices and institutional investors from both India and the US. Launched in July 2025, the fund aimed to invest in eight to ten early-stage healthtech startups across India and the US for a period of four years.
W Health Ventures' managing partner, Pankaj Jethwani, explained that the firm focuses on identifying promising healthtech concepts at an early stage and then forms a founding team around these ideas, supported by an in-house team of technologists, entrepreneurs, and clinicians. The company has already backed two startups with the second fund: Everhope Oncology, a cancer care platform partnered with Narayana Health, and Everbright Health, launched in the US alongside Sanos Capital.
Since its inception in 2020, W Health Ventures has been based in Mumbai and has built healthcare companies from pre-idea to category leader across the India-US corridor. The firm typically invests between ₹30 Cr and ₹50 Cr per startup and has backed 12 ventures in the region through its first fund, which included companies like Wysa, BeatO, Mylo, Reveal, and BabyMD.
The fund's close comes at a time when India's healthtech funding landscape is seeing a shift towards more selectivity and an increased focus on company creation, with investors looking to participate earlier in the development process.
Written by urgent.news from Inc42's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
